|本期目录/Table of Contents|

[1]袁冰绡,叶明翔,宋勇.肺癌相关静脉血栓栓塞症的危险因素及预测模型研究进展[J].医学研究与战创伤救治(原医学研究生学报),2023,25(1):75-79.[doi:10.3969/j.issn.1672-271X.2023.01.015]
　YUAN Bingxiao,YE Mingxiang,SONG Yong.Research advances of venous thromboembolism in patients with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(1):75-79.[doi:10.3969/j.issn.1672-271X.2023.01.015]
点击复制

肺癌相关静脉血栓栓塞症的危险因素及预测模型研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第25卷
期数:
2023年1期
页码:
75-79
栏目:
综述
出版日期:
2023-05-10

文章信息/Info

Title:
Research advances of venous thromboembolism in patients with lung cancer
作者:
袁冰绡; 叶明翔; 宋勇
作者单位：210002南京，南京医科大学金陵临床医学院（东部战区总医院）呼吸与危重症医学科（袁冰绡、叶明翔、宋勇）
Author(s):
YUAN Bingxiao;  YE Mingxiang ;  SONG Yong
(Department of Respiratory and Critical Care Medicine, Jinling Clinical College of Medicine, Nanjing Medical University/General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China）
关键词:
静脉血栓栓塞症; 肺癌; 危险因素; 风险评估模型
Keywords:
venous thromboembolism;  lung cancer;  risk factors;  risk assessment model
分类号:
R734.2
DOI:
10.3969/j.issn.1672-271X.2023.01.015
文献标志码:
A
摘要:
静脉血栓栓塞症（VTE）是肺癌最常见的并发症之一。VTE不仅会干扰凝血系统的平衡，还会影响肿瘤的进展和预后。患有VTE的癌症患者可能更易发生VTE复发和出血并发症，故预防及治疗肺癌相关VTE发生时需平衡出血与VTE发生的风险。为了识别肺癌相关VTE发生的高危患者，既往研究中已发现多种危险因素，开发并验证了相应的临床风险评估模型。随着肺癌治疗模式的进展，仍需进一步研究新型治疗模式对VTE发生的影响，探索新的危险因素及新型预测模型。文章主要就VTE预测和风险评估的进展进行综述。
Abstract:
Venous thromboembolism (VTE) is one of the most common complications of lung cancer. VTE interferes with the homeostasis of the coagulation system and affects tumor progression and prognosis. Cancer patients with VTE may be more prone to VTE recurrence and bleeding complications, so prevention and treatment of lung cancer-associated VTE requires balancing the risk of bleeding and VTE occurrence. In order to identify patients at high risk of developing lung cancer-associated VTE, various risk factors have been identified in previous studies, and corresponding clinical risk assessment models have been developed and validated. With the development of antineoplastic protocols, it is necessary to further investigate the impact of novel antineoplastic protocols on VTE occurrence and to explore new risk factors and novel prediction models. In this review, we summarize advances in VTE prediction and risk assessment models, focusing on the early diagnosis and treatment of lung cancer-associated VTE.

参考文献/References:

[1]马军, 秦叔逵, 吴一龙, 等. 肿瘤相关静脉血栓栓塞症预防与治疗指南（2019版）[J]. 中国肿瘤临床, 2019,46(13): 653-660.
[2]Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J]. J Thromb Haemost, 2007, 5(3): 632-634.
[3]Date K, Ettelaie C, Maraveyas A, Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer[J]. J Thromb Haemost, 2017, 15(12): 2289-2299.
[4]Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis[J]. Blood, 2008, 111(10): 4902-4907.
[5]Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS–Cancer-Associated Thrombosis Study[J]. Oncologist, 2017, 22(10): 1222-1231.
[6]Roselli M, Riondino S, Mariotti S, et al. Clinical models and biochemical predictors of VTE in lung cancer[J]. Cancer Metastasis Rev, 2014, 33(2-3): 771-789.
[7]Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer[J]. J Thromb Haemost, 2008, 6(4): 601-608.
[8]Rupa-Matysek J, Lembicz M, Rogowska EK, et al. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients[J]. Med Oncol, 2018, 35(5):63.
[9]Knigsbrügge O, Ltsch F, Reitter EM, et al. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism[J]. J Thromb Haemost, 2013, 11(11): 1993-2000.
[10]Ahlbrecht J, Dickmann B, Ay C, et al. Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study[J]. J Clin Oncol, 2012, 30(31): 3870-3875.
[11]Cronin-Fenton DP, Sndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006[J]. Br J Cancer, 2010. 103(7): 947-953.
[12]Loreto MF, De Martinis M, Corsi MP, et al. Coagulation and cancer: implications for diagnosis and management[J]. Pathol Oncol Res, 2000, 6(4): 301-312.
[13]Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma[J]. J Thromb Haemost, 2004, 2(10): 1760-1765.
[14]Walker AJ, Baldwin DR, Card TR, et al. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data[J]. Br J Cancer, 2016, 115(1): 115-121.
[15]Abufarhaneh M, Pandya RK, Alkhaja A, et al. Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis[J]. Thromb Res, 2022, 213: 47-56.
[16]Corrales-Rodriguez L, Soulières D, Weng X, et al. Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study[J]. Thromb Res, 2014, 133(1): 48-51.
[17]徐澄澄, 付向宁. 肺癌患者手术前后凝血状态的变化[J]. 中国肺癌杂志, 2010, 13(2): 136-139.
[18]Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis[J]. J Clin Oncol, 2011, 29(25): 3466-3473.
[19]Hill H, Robinson M, Lu L, et al. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy[J]. Thromb Res, 2021, 208: 71-78.
[20]Moik F, Chan W-SE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy[J]. Blood, 2021, 137(12): 1669-1678.
[21]Cánovas MS, Garay DF, Moran LO, et al. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group[J]. Clin Translat Oncol, 2022, 24(10): 2010-2020.
[22]Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients[J]. Clin Lung Cancer, 2012, 13(6): 482-487.
[23]Kadlec B, Skrickova J, Merta Z, et al. The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer[J]. Scient World J, 2014, 2014: 1-9.
[24]Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) [J]. Blood, 2008, 112(7): 2703-2708.
[25]Campello E, Spiezia L, Radu CM, et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism[J]. Thromb Res, 2011, 127(5): 473-477.
[26]刘燕娥, 顾阳春, 易福梅, 等. 283例系统性治疗的肺癌患者静脉血栓栓塞症的危险因素分析[J]. 中国肺癌杂志, 2019, 22(7): 419-426.
[27]Ferroni P, Riondino S, Formica V, et al. Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio[J]. Int J Cancer, 2015, 136(5): 1234-1240.
[28]Anghel L, Sascu R, Radu R, et al. From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis[J]. Int J Mol Sci, 2020, 21(6): 1920.
[29]Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score[J]. Intern Emerg Med, 2012, 7(3): 291-292.
[30]Pelzer U, Sinn M, Stieler J, et al. Primre medikamentse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie[J]? Deutsch Med Wochenschr, 2013, 138(41): 2084-2088.
[31]Alexander M, Ball D, Solomon B, et al. Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer[J]. Cancers, 2019, 11(1): 50.
[32]Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients[J]. Blood, 2010, 116(24): 5377-5382.
[33]Pabinger I, van Es N, Heinze G, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts[J]. Lancet Haematol, 2018,5(7): e289-e298.
[34]Cella CA, Di Minno G, Carlomagno C, et al. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study[J]. Oncologist, 2017,22(5): 601-608.
[35]Syrigos K, Grapsa D, Sangare R, et al. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study[J]. Oncologist, 2018, 23(11): 1372-1381.
[36]Lei H, Zhang M, Wu Z, et al. Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Lung Cancer Patients Using Machine Learning[J]. Front Cardiovasc Med, 2022, 9: 845210.
[37]Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update[J]. J Clin Oncol, 2020, 38(5): 496-520.
[38]Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer[J]. Lancet Oncol, 2019, 20(10): e566-e581.
[39]Tsoukalas N, Tsapakidis K, Galanopoulos M, et al. Real world data regarding the management of cancer-associated thrombosis[J]. Curr Opin Oncol, 2020, 32(4): 289-294.
[40]Haykal T, Zayed Y, Deliwala S, et al. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials[J]. Thromb Res, 2020, 194: 57-65.
[41]Ueyama H, Miyashita H, Takagi H, et al. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer[J]. J Thromb Thrombolysis, 2021, 51(1): 102-111.

相似文献/References:

[1]许德兵,胡 燕,王 颖,等.女性肺癌95例临床分析[J].医学研究与战创伤救治(原医学研究生学报),2013,15(03):255.[doi:10.3969/j.issn.1672-271X.2013.03.016]
　XU De-bing,HU Yan,WANG Ying,et al.Clinical analysis of 95 cases of female lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(1):255.[doi:10.3969/j.issn.1672-271X.2013.03.016]
[2]时维东,陶小红,丁汇清,等.女性肺癌的影像诊断与临床对照分析[J].医学研究与战创伤救治(原医学研究生学报),2013,15(01):35.
　SHI Wei-dong,TAO Xiao-hong,DING Hui-qing,et al.Imaging diagnosis and clinical comparative study of lung cancer in female[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(1):35.
[3]郑大东,钟 勇.肿瘤标志物及PET未见异常的肺癌1例[J].医学研究与战创伤救治(原医学研究生学报),2012,14(01):70.
[4]王 璇,时姗姗,马恒辉,等.非小细胞肺癌表皮生长因子受体基因突变的结果分析[J].医学研究与战创伤救治(原医学研究生学报),2012,14(05):387.
　WANG Xuan,SHI Shan-shan,MA Heng-hui,et al.Respective analysis of EGFR mutations in non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(1):387.
[5]周 源,汪 栋,张传生,等.肺癌患者术前病理诊断的临床意义[J].医学研究与战创伤救治(原医学研究生学报),2008,10(02):97.
　ZHOU Yuan,WANG Dong,ZHANG Chuan-sheng,et al.Clinical significance of preoperatively pathological diagnosis of lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2008,10(1):97.
[6]许德兵,潘士勇,史兆荣,等.肺癌合并胸腔积液172例临床分析[J].医学研究与战创伤救治(原医学研究生学报),2008,10(02):107.
　XU De-bing,PAN Shi-yong,SHI Zhao-rong,et al.Clinical analysis of 172 cases of malignant pleural effusion with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2008,10(1):107.
[7]庄聪文,翁向群,程先进,等.胺碘酮转复肺癌术后室上性心律失常的 疗效分析[J].医学研究与战创伤救治(原医学研究生学报),2008,10(04):252.
　ZHUANG Cong-wen,WENG Xiang-qun,CHENG Xian-jin,et al.Analysis of amiodarone therapy for supraventricular arrhythmias after operation in patients with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2008,10(1):252.
[8]许德兵,吴凌云综述,宋 勇审校.miRNA与肺癌关系的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2014,16(01):73.
[9]艾书跃,杨凤娇,袁 梅,等.原发性肺癌原发灶PET/CT征象与发生淋巴结及远处转移的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):138.[doi:10.3969/j.issn.1672-271X.2015.02.008]
　AI Shu-yue,YANG Feng-jiao,YUAN Mei,et al.Correlation between the PET/CT signs of primary lung cancer and metastases[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(1):138.[doi:10.3969/j.issn.1672-271X.2015.02.008]
[10]肖鑫武,孙文逵,刘亚芳,等.超声支气管镜引导下的经支气管镜针吸活检术在纵隔及肺部病变诊疗中的应用价值[J].医学研究与战创伤救治(原医学研究生学报),2015,17(03):239.[doi:10.3969/j.issn.1672-271X.2015.03.005]
　XIAO Xin-wu,SUN Wen-kui,LIU Ya-fang,et al.The application value of endobronchial ultrasound-guided transbronchial needle aspiration in diagnosis and treatment of mediastinal and pulmonary diseases[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(1):239.[doi:10.3969/j.issn.1672-271X.2015.03.005]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2023-04-19